November 20, 2025
Human medicines European public assessment report (EPAR): Teizeild, teplizumab, Status: Opinion
IntelME Verdict
Regulatory Approval
TL;DR
European Medicines Agency's CHMP issues positive opinion for Teizeild (teplizumab) to delay stage 3 type 1 diabetes onset, potentially becoming EU's first disease-modifying T1D therapy.
Analysis
The positive opinion by the CHMP for Teizeild (teplizumab) to delay stage 3 type 1 diabetes onset signifies a significant regulatory milestone. If approved, it would be the EU's first disease-modifying therapy for T1D, offering new treatment options and potentially impacting the landscape of T1D management and future drug development strategies.
Share: